🇺🇸 FDA

Intelligence · Patent portfolio

Vertex Pharmaceuticals (Australia) Patents

Full USPTO pharma patent portfolio for Vertex Pharmaceuticals (Australia) — grant dates, expiration, and drug cross-links.

Patents
991
Expiring ≤24m
63

Quick answer

Vertex Pharmaceuticals (Australia) has 991 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 63 expire within 24 months — use filters for patent-cliff planning.

Page 3 of 21

  1. US 11186566

    Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator

    Expires Mon Nov 25 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 11179367

    Pharmaceutical compositions for treating cystic fibrosis

    Expires Mon Nov 18 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 11179394

    Method for treating cancer using a combination of Chk1 and ATR inhibitors

    Expires Mon Nov 18 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 11155533

    Crystalline forms and compositions of CFTR modulators

    Expires Mon Oct 21 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 11147770

    Pharmaceutical composition and administrations thereof

    Expires Mon Oct 14 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 11124805

    Methods, compositions and kits for increasing genome editing efficiency

    Expires Mon Sep 16 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 11117900

    Compounds useful as inhibitors of ATR kinase

    Expires Mon Sep 09 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 11110086

    Compounds useful as inhibitors of ATR kinase and combination therapies thereof

    Expires Mon Sep 02 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 11110108

    Method for treating cancer using a combination of DNA-damaging agents and DNA-PK inhibitors

    Expires Mon Sep 02 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 11084804

    Modulators of ATP-binding cassette transporters

    Expires Mon Aug 05 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 11066417

    Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulators

    Expires Mon Jul 15 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 11059826

    Pteridinone compounds and uses thereof

    Expires Mon Jul 08 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 11052075

    Pharmaceutical compositions of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid and administration thereof

    Expires Mon Jul 01 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 11021465

    DNA-PK inhibitors

    Expires Mon May 27 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 11008305

    DNA-PK inhibitors

    Expires Mon May 13 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 10987348

    Modulators of ATP-binding cassette transporters

    Expires Mon Apr 22 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 10988477

    GCN2 inhibitors and uses thereof

    Expires Mon Apr 22 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 10980746

    Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases

    Expires Mon Apr 15 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 10973830

    Substituted quinoxaline DNA-PK inhibitors

    Expires Mon Apr 08 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 10975061

    Modulators of ATP-binding cassette transporters

    Expires Mon Apr 08 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 10961232

    Substituted pyrazines as ATR kinase inhibitors

    Expires Mon Mar 25 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 10913761

    2,7-dibromospiro[fluorene-9,4′-piperidine] compounds

    Expires Mon Feb 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 10906891

    Solid forms of (R)-1(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide

    Expires Mon Jan 28 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 10874673

    Inhibitors of influenza viruses replication

    Expires Mon Dec 24 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 10875855

    Inhibitors of influenza viruses replication

    Expires Mon Dec 24 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 10815225

    Antiproliferation compounds and uses thereof

    Expires Mon Oct 22 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 10815239

    Compounds useful as inhibitors of ATR kinase

    Expires Mon Oct 22 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 10813929

    Treating cancer with ATR inhibitors

    Expires Mon Oct 22 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 10801076

    Influenza A virus variants

    Expires Mon Oct 08 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 10800781

    Compounds useful as inhibitors of ATR kinase

    Expires Mon Oct 08 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 10793563

    GCN2 inhibitors and uses thereof

    Expires Mon Oct 01 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 10793547

    Modulator of the cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator

    Expires Mon Oct 01 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 10787472

    Prodrugs of pyridone amides useful as modulators of sodium channels

    Expires Mon Sep 24 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 10787452

    Compounds useful as inhibitors of ATR kinase

    Expires Mon Sep 24 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 10786512

    DNA-PK inhibitors

    Expires Mon Sep 24 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 10766869

    Triazoles for the treatment of demyelinating dieases

    Expires Mon Sep 03 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 10758534

    Modulators of cystic fibrosis transmembrane conductance regulator

    Expires Mon Aug 27 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 10759721

    Deuterated CFTR potentiators

    Expires Mon Aug 27 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 10738027

    Crystalline forms of C21H22Cl2N4O2

    Expires Mon Aug 06 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 10738030

    Modulators of cystic fibrosis transmembrane conductance regulator

    Expires Mon Aug 06 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 10738009

    Pyridone amides as modulators of sodium channels

    Expires Mon Aug 06 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 10738036

    Deuterated CFTR modulators

    Expires Mon Aug 06 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 10738305

    Materials and methods for treatment of hemoglobinopathies

    Expires Mon Aug 06 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 10716789

    Co-crystals and pharmaceutical compositions comprising the same

    Expires Mon Jul 16 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 10669298

    Mannose derivatives for treating bacterial infections

    Expires Mon May 28 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 10662192

    Modulators of ATP-binding cassette transporters

    Expires Mon May 21 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 10654829

    Crystalline forms and compositions of CFTR modulators

    Expires Mon May 14 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 10647661

    Carboxamides as modulators of sodium channels

    Expires Mon May 07 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many patents does Vertex Pharmaceuticals (Australia) have?

991 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do Vertex Pharmaceuticals (Australia) patents expire?

63 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.

Where does this data come from?

USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.

Data attribution: Data sources · Patent directory

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.